DNA定量分析联合hMSH6检测在宫颈癌筛查中的意义

目的 探讨DNA异倍体分析与hMSH6及HPV在宫颈癌变过程中的相关性及临床意义。方法 采用高危型HPV-DNA检测及免疫组化hMSH6染色,分析不同病变宫颈组织中hMSH6表达、HPV感染情况及相关性。结果 以DNA异倍体出现和中量DNA异倍体出现为活检标准,宫颈病变的特异性和敏感性分别为25.86%和77.59%。提示中量以上DNA异倍体出现对宫颈病变筛查具有较高的诊断价值。多量、中量异倍体组hMSH6阳性率分别为75％和85.71%,与对照组间比较,P＜0.05。多量、中量DNA异倍体组HPV感染率分别为92.86%和76.19%,与对照组间比较,P＜0.05。HPV感染多量倍体异常组hMSH6阳性率为90.38%,与无HPV感染多量倍体异常组MSH6阳性率25%比较,P＜0.05。结论 HPV联合hMSH6检测是针对病因的检测,敏感性高。HPV感染导致hMSH6蛋白高表达,有望为宫颈癌的防治提供参考依据。

The significance of DNA quantitative analysis combined with hMSH6 in cervical cancer screening

Objective To investigate the correlation and clinical significance of DNA ploidy analysis with hMSH6 and HPV in cervical cancer. Methods High risk HPV-DNA detection and immunohistochemical hMSH6 staining were used to analyze the expression of hMSH6, HPV infection and correlation in cervical tissues with different lesions. Results The specificity of cervical lesions was 25.86% and 77.59%, respectively, based on the presence of DNA aneuploidy and moderate amount of DNA aneuploidy. It suggests that the presence of more than moderate amount of DNA aneuploidy has a higher diagnostic value for cervical lesions screening. The positive rates of hMSH6 were 75% and 85.71% in the multidose and medium dose alloploid groups, which had statistically significant differences from the control group (P＜0.05). The infection rate of HPV was 92.86% and 76.19% in the multi-dose and medium-dose DNA aneuploidy groups,which showing statistically significant differences from the control group (P＜0.05). The MSH6 positive rate of the multiploidy abnormal HPV infection group was 90.38%, which was different from the MSH6 positive rate of the multiploidy abnormal HPV infection group 25% (P＜0.05) Conclusion HPV combined with hMSH6 test is the detection of etiology, with high sensitivity. The high expression of hMSH6 protein caused by HPV infection is expected to provide a reference for the prevention and treatment of cervical cancer.